1. Volume 155, Issue 3, Pages 705-718 (September 2018)
Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia 
Norah Terrault, Yi-Cheng Chen, Namiki Izumi, Zeid Kayali, Paul Mitrut, Won Young Tak, Lee F. Allen, Tarek Hassanein 
Gastroenterology 
Volume 155, Issue 3, Pages (September 2018)
DOI: /j.gastro
Copyright © 2018 AGA Institute Terms and Conditions

2. Gastroenterology 2018 155, 705-718DOI: (10.1053/j.gastro.2018.05.025)
Copyright © 2018 AGA Institute Terms and Conditions

3. Figure 1
Overview of the phase 3 studies ADAPT-1 and ADAPT-2 (A) Study design. aVisit 3 occurred on day 4 (±1 day) during the treatment period. (B) Patient disposition. PLT, platelet count; R, ratio.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2018 AGA Institute Terms and Conditions

4. Figure 2
ADAPT-1 and ADAPT-2 efficacy endpoints. (A) Proportion of patients not requiring a platelet transfusion or any rescue procedure for bleeding. (B) Proportion of patients who achieved platelet counts ≥ 50 × 109/L on procedure day. (C) Magnitude of change in platelet count from baseline to procedure day. Full analysis set. Difference in change from baseline of platelet count for avatrombopag vs placebo within each cohort was based on Hodges-Lehmann estimation.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2018 AGA Institute Terms and Conditions

5. Figure 3
Mean platelet counts by treatment group and visit day. (A) ADAPT-1. (B) ADAPT-2.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2018 AGA Institute Terms and Conditions